Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis

Dual-action pro-drugs (e.g. 9) target and bind to bone in vivo and slowly release the bone resorption inhibitor, alendronic acid (1) and the bone growth stimulant EP4 receptor selective agonist (5) in situ.